Dec 30 (Reuters) - OPKO Health Inc said its
experimental drug for growth hormone deficiency (GHD) in adults
failed to provide a statistically significant benefit over a
placebo in a late-stage study, sending its shares down 14
percent in early trading.
Read more
No comments:
Post a Comment